RESEARCH TRIANGLE PARK, N.C.,
Sept. 11, 2019 /PRNewswire/
-- Pappas Capital, a leading investor in early-stage life
sciences companies, announced today that Alex Arfaei has joined the firm as a Partner of
Pappas Ventures. In his role, Mr. Arfaei will be responsible for
helping to identify and evaluate investment opportunities for the
firm's venture capital business. Previously, Mr. Arfaei served as a
Managing Director with BMO Capital Markets, where he was a senior
equity research analyst covering major pharmaceutical and
biotechnology companies.
"Alex's unique combination of equity research and industry
operating experience will significantly benefit our team as we seek
to source innovative investment opportunities for the current and
future Pappas Ventures funds," said Art
Pappas, founder and Managing Partner of Pappas Capital. "We
are pleased to welcome Alex to Pappas as we continue to execute on
our mission of delivering superior returns for our clients by
investing in companies creating the next generation of life science
products and technologies."
Mr. Arfaei added, "Pappas Capital is well-recognized for being a
proven leader in advancing life science, and I am thrilled to join
the firm at this exciting time in its evolution. I look forward to
building on the firm's strong investment track record by helping to
develop innovative companies that address unmet needs for patients
and shape the future of medicine."
Mr. Arfaei's appointment further strengthens the firm's
leadership team following the promotions of Kyle Rasbach, PhD, PharmD to a Managing Partner
of Pappas Ventures and Matthew Boyer
to Chief Financial Officer, as well as the hiring of Tom Mathers as a Partner of Pappas Ventures.
Mr. Arfaei brings over a decade of biotechnology and
pharmaceutical equity research experience to Pappas Capital. Prior
to BMO, Mr. Arfaei was an equity research analyst at FBR Capital
Markets. Previously, he held operating roles at Endo
Pharmaceuticals Inc. and Merck. Mr. Arfaei received a BS in Cell
and Molecular Biology from the University of
Toronto and an MBA from Duke
University.
About Pappas Capital
Founded in 1994, Pappas Capital invests exclusively in innovative
life sciences companies with a focus on biotechnology,
biopharmaceuticals, drug delivery, medical devices and related
ventures, across the United States
and Canada. Pappas Capital has
raised more than $540 million and has
guided the launch or development of more than 85 companies. In
addition to its Pappas Ventures funds, the firm manages customized
investment vehicles for third parties through its Specialized Fund
Management Group and works with academic institutions in developing
innovation through its Translational Medicine Research Initiative.
For more information, please visit: www.pappas-capital.com.
Investor Contact:
Lisa Dreyer
919-998-3308
ldreyer@pappas-capital.com
Media Contact:
Amanda
Klein/Alex Jeffrey
Gasthalter & Co.
212-257-4170
View original content to download
multimedia:http://www.prnewswire.com/news-releases/alex-arfaei-joins-pappas-capital-as-partner-300915819.html
SOURCE Pappas Capital